July 23rd, 2020 – Biberach (Baden-Württemberg – Germany) and Schlieren (Zürich – Switzerland)
Biognosys announced today that it started working together with Boehringer Ingelheim. Here, Biognosys and Boehringer Ingelheim will team up to expand next-generation proteomics applications in drug discovery programs at Boehringer Ingelheim.
As a proof-of-concept, the companies perform comprehensive proteome profiling of a preclinical mouse model of idiopathic pulmonary fibrosis (IPF) to gain new insights into the disease biology. Using Biognosys’ single-shot HRM/DIA mass spectrometry, over 8’000 proteins can be quantified across a large number of lung tissue samples. The data will serve as a rich resource for the development of novel therapeutic strategies.
“This collaboration is a great example of how proteomics technologies are becoming essential tools in drug discovery programs. We are committed to working closely with Boehringer Ingelheim to make discovery proteomics an integral part of preclinical research,” said Dr. Oliver Rinner, CEO at Biognosys.
The initial focus of the activities will be on applications for fibrotic diseases. Boehringer Ingelheim also plans to implement the single-shot HRM/DIA capability in-house, using Biognosys’ Spectronaut™ software.
Head of Business Development
Mobile +41 (0) 78 664 47 11
About HRM Discovery Proteomics
Hyper Reaction Monitoring (HRM) is a label-free discovery proteomics workflow invented at Biognosys. It allows an unmatched proteome coverage with reproducible and precise quantification of up to 10’000 proteins per sample. Biognosys’ HRM™ technology platform provides deep biological insights from diverse sample types. These insights help biopharma researchers understand disease biology, reveal drug mode-of-action and discovery new biomarkers, and therefore accelerate the path to safer and more effective drugs.
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by making the most advanced proteomics tools available to researchers. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with a deep view of protein expression in cells, tissues, or body fluids. Biognosys’ technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at: www.biognosys.com.
About Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of
19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.